platinum compounds

Summary

Summary: Inorganic compounds which contain platinum as the central atom.

Top Publications

  1. Konstantinopoulos P, Spentzos D, Karlan B, Taniguchi T, Fountzilas E, Francoeur N, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 2010;28:3555-61 pubmed publisher
    ..To define a gene expression profile of BRCAness that correlates with chemotherapy response and outcome in epithelial ovarian cancer (EOC)...
  2. Silva H, Frezard F, Peterson E, Kabolizadeh P, Ryan J, Farrell N. Heparan sulfate proteoglycan-mediated entry pathway for charged tri-platinum compounds: differential cellular accumulation mechanisms for platinum. Mol Pharm. 2012;9:1795-802 pubmed publisher
  3. Burger H, Zoumaro Djayoon A, Boersma A, Helleman J, Berns E, Mathijssen R, et al. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br J Pharmacol. 2010;159:898-908 pubmed publisher
    ..As decreased drug accumulation is a key mechanism of platinum resistance, SLCs may also contribute to the development of resistance. Here, we define the role of hSLC22A2 (OCT2) in the cellular uptake of platinum compounds.
  4. Woolston C, Deen S, Al Attar A, Shehata M, Chan S, Martin S. Redox protein expression predicts progression-free and overall survival in ovarian cancer patients treated with platinum-based chemotherapy. Free Radic Biol Med. 2010;49:1263-72 pubmed publisher
    ..038), and was independent of other clinical parameters (p=0.048). Such results support the suitability of using redox protein expression to predict response and, potentially, to alter treatment options accordingly...
  5. Cossa G, Gatti L, Zunino F, Perego P. Strategies to improve the efficacy of platinum compounds. Curr Med Chem. 2009;16:2355-65 pubmed
    ..In addition to mononuclear platinum compounds, multinuclear platinum complexes have been generated that are characterised by a different mode of ..
  6. du Bois A, Reuss A, Pujade Lauraine E, Harter P, Ray Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialk. Cancer. 2009;115:1234-44 pubmed publisher
    ..However, the prognostic role of complete and so-called optimal and suboptimal debulking and its interaction with biological factors has not been not fully defined...
  7. Katsumata N, Fujiwara Y, Kamura T, Nakanishi T, Hatae M, Aoki D, et al. Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based. Jpn J Clin Oncol. 2008;38:777-85 pubmed publisher
    ..This study was conducted to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) in Japanese patients with Müllerian carcinoma having a therapeutic history of platinum-based chemotherapy...
  8. McGregor T, Hegmans A, Kasparkova J, Neplechová K, Novakova O, Penazova H, et al. A comparison of DNA binding profiles of dinuclear platinum compounds with polyamine linkers and the trinuclear platinum phase II clinical agent BBR3464. J Biol Inorg Chem. 2002;7:397-404 pubmed
    ..It can be concluded that dinuclear Pt compounds are similar to their trinuclear counterpart, and that charge differences do not contribute solely to the variances between the compounds...
  9. Giachino D, Ghio P, Regazzoni S, Mandrile G, Novello S, Selvaggi G, et al. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res. 2007;13:2876-81 pubmed
    ..This study aimed to investigate the relationship between the XPD Lys751Gln and XRCC1 Arg399Gln genotypes and outcome in lung cancer patients...

More Information

Publications93

  1. De Smet F, Pochet N, Engelen K, Van Gorp T, Van Hummelen P, Marchal K, et al. Predicting the clinical behavior of ovarian cancer from gene expression profiles. Int J Gynecol Cancer. 2006;16 Suppl 1:147-51 pubmed
    ..92% for the distinction between platin-resistant versus platin-sensitive disease in FIGO stage III/IV. These results indicate that gene expression patterns could be useful in clinical management of ovarian cancer...
  2. Reedijk J. New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA. Proc Natl Acad Sci U S A. 2003;100:3611-6 pubmed
    ..A comparison is made with more sterically crowded Ru complexes. The effects on activity and correlations with structural and kinetic properties are clues in understanding the biological activities of these classes of compounds...
  3. Gatti L, Supino R, Perego P, Pavesi R, Caserini C, Carenini N, et al. Apoptosis and growth arrest induced by platinum compounds in U2-OS cells reflect a specific DNA damage recognition associated with a different p53-mediated response. Cell Death Differ. 2002;9:1352-9 pubmed
    ..In this study, we investigated the cellular effects of exposure to two platinum compounds (cisplatin and the multinuclear platinum complex BBR 3464), in the osteosarcoma cell line, U2-OS, carrying ..
  4. Hann S, Stefánka Z, Lenz K, Stingeder G. Novel separation method for highly sensitive speciation of cancerostatic platinum compounds by HPLC-ICP-MS. Anal Bioanal Chem. 2005;381:405-12 pubmed
    ..In a second step of the study the method was successfully evaluated for monitoring cancerostatic platinum compounds in hospital waste water.
  5. Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol. 2002;42:317-25 pubmed
    ..Oxaliplatin give interesting results in a number of cancers. The official recommendation in Japan for nedaplatin is head and neck, testicular, lung, oesophageal, ovarian, and cervical cancer...
  6. Benedetti V, Perego P, Luca Beretta G, Corna E, Tinelli S, Righetti S, et al. Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds. Mol Cancer Ther. 2008;7:679-87 pubmed publisher
  7. Vekris A, Meynard D, Haaz M, Bayssas M, Bonnet J, Robert J. Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research. Cancer Res. 2004;64:356-62 pubmed
    ..In an attempt to study the molecular determinants of the activity of platinum compounds, we explored the publicly available databases of the National Cancer Institute (NCI; http://dtp.nci.nih...
  8. Linnett P, Hughes E. 20 years of medical surveillance on exposure to allergenic and non-allergenic platinum compounds: the importance of chemical speciation. Occup Environ Med. 1999;56:191-6 pubmed
    Chloroplatinates are potent allergens but other soluble platinum compounds such as tetraammine platinum dichloride (TPC) do not provoke reactions in subjects who are sensitive to chloroplatinates...
  9. Hess V, A Hern R, Nasiri N, King D, Blake P, Barton D, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol. 2004;22:1040-4 pubmed
    ..Chemotherapy for mEOC is chosen according to guidelines established for EOC. The purpose of this study is to determine whether this is appropriate...
  10. Olas B, Wachowicz B, Majsterek I, Blasiak J. Resveratrol may reduce oxidative stress induced by platinum compounds in human plasma, blood platelets and lymphocytes. Anticancer Drugs. 2005;16:659-65 pubmed
    ..F(2) (a biomarker of lipid peroxidation) in control blood platelets and platelets treated with platinum compounds (10 microg/ml), and markedly reduced activities of different anti-oxidative enzymes (glutathione peroxidase, ..
  11. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7:573-84 pubmed
  12. Polyzos A, Kosmas C, Tsavaris N, Toufexi H, Lagadas A, Gogas H, et al. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel. Anticancer Res. 2007;27:1645-51 pubmed
    ..chemotherapy regimens in the management of ovarian cancer patients with tumors previously exposed to platinum compounds and paclitaxel has not yet been defined...
  13. Pasetto L, D Andrea M, Brandes A, Rossi E, Monfardini S. The development of platinum compounds and their possible combination. Crit Rev Oncol Hematol. 2006;60:59-75 pubmed
    ..any definitive, biologically interpretable molecular predictor of activity is consistent with the idea that platinum compounds have multiple intracellular targets and that cells can have multiple mechanisms of resistance...
  14. Wu X, Gu J, Wu T, Swisher S, Liao Z, Correa A, et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol. 2006;24:3789-98 pubmed
    ..Understanding how specific genetic variants modify drug action pathways may provide informative blueprints for individualized chemotherapy...
  15. Farrell N. Preclinical perspectives on the use of platinum compounds in cancer chemotherapy. Semin Oncol. 2004;31:1-9 pubmed
    Although platinum compounds have long been used in cancer chemotherapy, understanding the biochemistry and specific activity of these agents remains a focus of ongoing research, particularly with regard to next-generation platinum agents...
  16. Rabik C, Dolan M. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33:9-23 pubmed
    ..Although the purpose of this review is to provide an overview of cisplatin, carboplatin, and oxaliplatin, we have focused primarily on preclinical data that has clinical relevance generated over the past five years...
  17. Barlesi F, Pujol J. Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: a systematic review of phase III trials. Lung Cancer. 2005;49:289-98 pubmed
  18. Galanski M, Jakupec M, Keppler B. Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr Med Chem. 2005;12:2075-94 pubmed
    ..It focuses also on innovative synthetic strategies leading to novel classes of platinum complexes. A small part of the review is dedicated to new analytical approaches which have been supplied to or emerged in this field of research...
  19. Pelissier A, Bonneau C, Chereau E, de La Motte Rouge T, Fourchotte V, Darai E, et al. Dynamic Analysis of CA125 Decline During Neoadjuvant Chemotherapy in Patients with Epithelial Ovarian Cancer as a Predictor for Platinum Sensitivity. Anticancer Res. 2016;36:1865-71 pubmed
    ..8-times more at risk for PFI <12 months (95% CI=1.7-8.5, p<0.001). A CA125 level after the 3rd NAC <35 UI/ml is an independent predictor for tumor platinum-sensitivity. ..
  20. Ihrlund L, Hernlund E, Khan O, Shoshan M. 3-Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs. Mol Oncol. 2008;2:94-101 pubmed publisher
    ..Together with the reported lack of toxicity, this indicates the potential of BP as a clinical chemopotentiating agent. ..
  21. Wang Q, Chen Q, Zhu L, Chen M, Xu W, Panday S, et al. JWA regulates TRAIL-induced apoptosis via MARCH8-mediated DR4 ubiquitination in cisplatin-resistant gastric cancer cells. Oncogenesis. 2017;6:e353 pubmed publisher
    ..Drug resistance to platinum compounds may result in cancer relapse and decreased survival...
  22. Fiebiger W, Olszewski U, Ulsperger E, Geissler K, Hamilton G. In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines. Clin Transl Oncol. 2011;13:43-9 pubmed publisher
    ..In summary, among the novel platinum drugs satraplatin has the potential for treatment of lung carcinoids and DCA potentiates the cytotoxicity of selected platinum drugs. ..
  23. Salim H, Zong D, Hååg P, Novak M, Mörk B, Lewensohn R, et al. DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines. BMC Cancer. 2015;15:628 pubmed publisher
    b>Platinum compounds are the mainstay of chemotherapy for lung cancer. Unfortunately treatment failure remains a critical issue since about 60% of all non-small cell lung cancer (NSCLC) patients display intrinsic platinum resistance...
  24. Burger M, Kramer J, Chermette H, Koch K. A comparison of experimental and DFT calculations of ¹??Pt NMR shielding trends for [PtX(n)Y(6-n)](2-) (X, Y = Cl, Br, F and I) anions. Magn Reson Chem. 2010;48 Suppl 1:S38-47 pubmed publisher
  25. Allardyce C, Dyson P. Metal-based drugs that break the rules. Dalton Trans. 2016;45:3201-9 pubmed publisher
    Cisplatin and other platinum compounds have had a huge impact in the treatment of cancers and are applied in the majority of anticancer chemotherapeutic regimens...
  26. Modena A, Iacovelli R, Scarpa A, Brunelli M, Ciccarese C, Fantinel E, et al. Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer. Target Oncol. 2016;11:569-577 pubmed
    ..synthetic lethality" of this disease might be useful in cancer-drug discovery, focusing on agents such as platinum compounds and poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPi)...
  27. Yu Y, Chen Z, Zhou Z, Song Z, Li Z, Jian H, et al. A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China. Chemotherapy. 2010;56:472-7 pubmed publisher
    ..The medical expenses associated with doublet therapy were much higher than those associated with single therapy with a significant portion of the medical expenses spent on treating hematological and gastrointestinal toxicity. ..
  28. Ma Z, Rao L, Bierbach U. Replacement of a thiourea-S with an amidine-NH donor group in a platinum-acridine antitumor compound reduces the metal's reactivity with cysteine sulfur. J Med Chem. 2009;52:3424-7 pubmed publisher
    ..Possible consequences of the unique target-selective tuning of the substitution chemistry for the pharmacodynamic properties and biological activity of these agents are discussed. ..
  29. Vergote I, Garcia A, Micha J, Pippitt C, Bendell J, Spitz D, et al. Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer. J Clin Oncol. 2013;31:4060-6 pubmed publisher
    ..These findings provide support to directly compare etirinotecan pegol versus one of the approved drugs (eg, pegylated liposomal doxorubicin or topotecan) in platinum-resistant ovarian cancer. ..
  30. Ferrandina G, Salutari V, Vincenzi B, Marinaccio M, Naglieri E, Loizzi V, et al. Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: a retrospective, multicenter study. Gynecol Oncol. 2013;130:505-10 pubmed publisher
    ..Trabectedin, as a single agent, retains its efficacy in terms of rate of ORR and clinical benefit in heavily treated ROC patients, especially in the group of platinum sensitive disease. ..
  31. Craiu A. [Corneal tatoo--art or science?]. Oftalmologia. 2009;53:97-103 pubmed
    ..Because of improvement in surgical reconstructive techniques, corneal tattoing is used today only with a restricted group on carefully chosen patients, and merely for esthetique reasons. ..
  32. Davidoff A, Tang M, Seal B, Edelman M. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:2191-7 pubmed publisher
    ..The benefit of platinum-based doublet regimens is greater than single-agent chemotherapy. Claims-based proxy indicators of poor PS were independent predictors of treatment and merit further exploration. ..
  33. Giannatempo P, Pond G, Sonpavde G, Raggi D, Naik G, Galsky M, et al. The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016;69:624-633 pubmed publisher
    ..More effective taxanes should be investigated further in urothelial carcinoma in combination with gemcitabine/platinum. ..
  34. Leung K, Saif M. BRCA-associated pancreatic cancer: the evolving management. JOP. 2013;14:149-51 pubmed publisher
    ..We will review these abstracts and our current knowledge of the treatment for patients with BRCA-associated pancreatic cancer. In this group of patients, these new results continue to shape our understanding of this disease. ..
  35. Che C, Siu F. Metal complexes in medicine with a focus on enzyme inhibition. Curr Opin Chem Biol. 2010;14:255-61 pubmed publisher
    ..This review highlights some exciting results published recently on the development of platinum, gold, and ruthenium complexes as enzyme inhibitors for potential therapeutic applications...
  36. Vencken P, Reitsma W, Kriege M, Mourits M, de Bock G, de Hullu J, et al. Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands. Ann Oncol. 2013;24:2036-42 pubmed publisher
    ..While response rates after primary treatment were similarly high in both groups, TFI, as surrogate for chemosensitivity, was significantly longer in BRCA2 patients. ..
  37. Lee J, Hahn S, Kim D, Kim J, Kang S, Rha S, et al. Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis. Br J Cancer. 2013;108:39-48 pubmed publisher
    ..Although no effective therapies have been established, this meta-analysis helps to fill an important gap of evidence. However, caution should still be taken because of the potential unmeasured confounding. ..
  38. Shah N, Dizon D. New-generation platinum agents for solid tumors. Future Oncol. 2009;5:33-42 pubmed publisher
    ..If successful, they may inspire a new effort to bring better-designed platinum agents to market. This article reviews the clinical development of platinum agents to date and speculates on the role of platinum agents in the near future. ..
  39. Zalba S, Garrido M. Liposomes, a promising strategy for clinical application of platinum derivatives. Expert Opin Drug Deliv. 2013;10:829-44 pubmed publisher
    ..Thermosensitive or targeted liposomes for tumor therapy are also included in this review. Few articles about this strategy applied to platinum drugs can be found in the literature. ..
  40. Zhong R, Teng J, Han B, Zhong H. Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother. 2011;60:1497-502 pubmed publisher
    ..Overall survival rate showed no statistically difference between two groups (P = 0.18). Chemoimmunotherapy could alleviate adverse effects of conventional chemotherapy and prolong survival for patients with late-stage NSCLC. ..
  41. Roque D, Bellone S, English D, Buza N, Cocco E, Gasparrini S, et al. Tubulin-?-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones. Cancer. 2013;119:2582-92 pubmed publisher
    ..Immunohistochemistry reliably identifies tumors with overexpression of tubulin-?-III, and a subset of individuals likely to respond to patupilone and ixabepilone. Epothilones warrant clinical investigation for treatment of USCs. ..
  42. Wu W, Zhang Y, Zeng Z, Li X, Hu K, Luo H, et al. ?-phenylethyl isothiocyanate reverses platinum resistance by a GSH-dependent mechanism in cancer cells with epithelial-mesenchymal transition phenotype. Biochem Pharmacol. 2013;85:486-96 pubmed publisher
    ..Taken together, our study shows a promising therapeutic strategy to overcome drug resistance to platinum-based chemotherapy and may potentially have broad implications in clinical treatment of cancer. ..
  43. Reck M, Rodriguez Abreu D, Robinson A, Hui R, Csöszi T, Fülöp A, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375:1823-1833 pubmed
    ..Funded by Merck; KEYNOTE-024 ClinicalTrials.gov number, NCT02142738 .). ..
  44. Bellmunt J, de Wit R, Vaughn D, Fradet Y, Lee J, Fong L, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017;376:1015-1026 pubmed publisher
    ..Funded by Merck; KEYNOTE-045 ClinicalTrials.gov number, NCT02256436 .). ..
  45. Shahzad M, Lopez Berestein G, Sood A. Novel strategies for reversing platinum resistance. Drug Resist Updat. 2009;12:148-52 pubmed publisher
    ..The most important targets highlighted here include Aurora kinases, PARP, ATP7B, and ERCC1. Furthermore, we discuss the implications of these novel approaches for ovarian cancer treatment. ..
  46. Nishio S, Katsumata N, Matsumoto K, Tanabe H, Yonemori K, Kouno T, et al. Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy. J Cancer Res Clin Oncol. 2009;135:551-7 pubmed publisher
    ..In this setting, however, both of these variables are subject to several well-established potential biases and limitations; further prospective studies are thus needed. ..
  47. Tassi R, Todeschini P, Siegel E, Calza S, Cappella P, Ardighieri L, et al. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. J Exp Clin Cancer Res. 2017;36:63 pubmed publisher
    ..in EOC cell lines inhibited cell growth and clonogenicity, and promoted the cytotoxic effects of platinum compounds, doxorubicin hydrochloride and olaparib...
  48. Cho S, Mei X, Ouyang J. Direct deposition of gold nanoplates and porous platinum on substrates through solvent-free chemical reduction of metal precursors with ethylene glycol vapor. Phys Chem Chem Phys. 2012;14:15793-801 pubmed publisher
    ..In contrast, the reduction of H(2)PtCl(6) gives rise to a 3-dimensional porous Pt structure on substrates. The different morphologies of nanostructured Au and Pt are tentatively related to the different surface energies of Au and Pt. ..
  49. Wu S, Zhao X, Meng X, Du M, Zhang S, Wang T, et al. [Analysis of chemotherapeutic efficacies in metastatic triple-negative breast cancer]. Zhonghua Yi Xue Za Zhi. 2012;92:3001-3 pubmed publisher
    ..The combined chemotherapy of platinum may achieve better efficacies in the treatment of metastatic triple-negative breast cancer. And the efficacies of first-line chemotherapy are closely correlated with survival. ..
  50. Zhang J, Li Y, Sun J, Li W, Gong Y, Zheng X, et al. Synthesis, cytotoxicity and DNA-binding levels of new type binuclear platinum(II) complexes. Eur J Med Chem. 2009;44:4772-7 pubmed publisher
    ..The new type binuclear platinum(II) complexes represent a novel class of anticancer agents, which deserves further attention in search of anticancer lead compounds. ..
  51. Yin M, Yan J, Voutsina A, Tibaldi C, Christiani D, Heist R, et al. No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer. 2011;72:370-7 pubmed publisher
    ..The nucleotide excision repair (NER) pathway modulates platinum-based chemotherapeutic efficacy by removing drug-induced DNA damage...
  52. Tagawa T, Iwata T, Nakajima T, Suzuki H, Yoshida S, Yoshino I. Evolution of a Lung-Sparing Strategy with Sleeve Lobectomy and Induction Therapy for Non-small Cell Lung Cancer: 20-Year Experience at a Single Institution. World J Surg. 2016;40:906-12 pubmed publisher
    ..25 (PN: 8, SL: 34), respectively. A lung-sparing strategy with SL for NSCLC can decrease the PN rate to less than 2 % with less mortality. Induction therapy may facilitate SL and increase the PN:SL ratio. ..
  53. Jett J, Schild S, Kesler K, Kalemkerian G. Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e400S-e419S pubmed publisher
    ..Our goal was to revise the evidence-based guidelines on staging and best available treatment options...
  54. Yoon D, Ryu M, Park Y, Lee H, Lee C, Ryoo B, et al. Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer. 2012;106:1039-44 pubmed publisher
    ..To evaluate the activity and safety of everolimus and identify potential biomarkers for efficacy of everolimus in patients with advanced gastric cancer (AGC), who failed both fluoropyrimidine and platinum...
  55. Li Z, Badaeva E, Ugrinov A, Kilina S, Sun W. Platinum chloride complexes containing 6-[9,9-di(2-ethylhexyl)-7-R-9H-fluoren-2-yl]-2,2'-bipyridine ligand (R = NO2, CHO, benzothiazol-2-yl, n-Bu, carbazol-9-yl, NPh2): tunable photophysics and reverse saturable absorption. Inorg Chem. 2013;52:7578-92 pubmed publisher
    ..This makes complexes 1-6, especially 6, very promising reverse saturable absorbers. ..
  56. Friedlander M, Butow P, Stockler M, Gainford C, Martyn J, Oza A, et al. Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer. Int J Gynecol Cancer. 2009;19 Suppl 2:S44-8 pubmed publisher
    ..In addition, this study will give us an insight into how all patients are managed rather than a select minority who are treated in clinical trials. ..
  57. Vujić J, Kaluđerović G, Milovanovic M, Zmejkovski B, Volarevic V, Zivić D, et al. Stereospecific ligands and their complexes. Part VII. Synthesis, characterization and in vitro antitumoral activity of platinum(II) complexes with O,O'-dialkyl esters of (S,S)-ethylenediamine-N,N'-di-2-(4-methyl)pentanoic acid. Eur J Med Chem. 2011;46:4559-65 pubmed publisher
    ..Cytotoxic effect of platinum(II) complexes on CLL cells was higher compared to corresponding palladium(II) complexes. In addition the mode of cell death induced by platinum(II) complexes was determined...
  58. Hong H, Hu L, Li M, Zheng J, Sun X, Lu X, et al. Preparation of Pt@Fe2O3 nanowires and their catalysis of selective oxidation of olefins and alcohols. Chemistry. 2011;17:8726-30 pubmed publisher
    ..5 h(-1)) than other reported Fe(2)O(3) nanoparticle catalysts and could be recycled multiple times without any notable decrease in activity. Our findings will extend the use of such nanomaterial catalysts to new catalytic systems...
  59. Serpeloni J, Batista B, Angeli J, Barcelos G, Bianchi M, Barbosa F, et al. Antigenotoxic properties of chlorophyll b against cisplatin-induced DNA damage and its relationship with distribution of platinum and magnesium in vivo. J Toxicol Environ Health A. 2013;76:345-53 pubmed publisher
    ..Thus, our results indicate that consumption of CLb-rich foods may diminish the adverse health effects induced by cDDP exposure...
  60. Campedel L, Kossai M, Blanc Durand P, Roupret M, Seisen T, Comperat E, et al. [Neuroendocrine prostate cancer: Natural history, molecular features, therapeutic management and future directions]. Bull Cancer. 2017;104:789-799 pubmed publisher
    ..This may also allow identifying diagnostic and prognostic biomarkers as well as potential molecular targets. However, treatment options are currently limited and consist only in platinium-based chemotherapy for advanced stage disease. ..
  61. Gupta D, Nowak R, Lippert B. Pt(II) complexes of unsubstituted guanine and 7-methylguanine. Dalton Trans. 2010;:73-84 pubmed publisher
    ..86 +/- 0.45 and 8.00 +/- 0.08 (average for deprotonation of two 7-MeGH ligands). Structural peculiarities of N9 platinated guanine ligands are discussed and pKa values of Pt complexes with related guanine nucleobases are compared...
  62. Hubner R, Goldstein R, Mitchell S, Jones A, Ashley S, O Brien M, et al. Influence of co-morbidity on renal function assessment by Cockcroft-Gault calculation in lung cancer and mesothelioma patients receiving platinum-based chemotherapy. Lung Cancer. 2011;73:356-60 pubmed publisher
    ..Co-morbidity, age, and renal impairment influence the accuracy of CG, whilst the relationship between CG and EDTA has been poorly assessed in lung cancer patients, a population significantly affected by these covariates...
  63. Koo C, Wong K, Man C, Lam Y, So L, Tam H, et al. A bioaccumulative cyclometalated platinum(II) complex with two-photon-induced emission for live cell imaging. Inorg Chem. 2009;48:872-8 pubmed publisher
    ..Cytotoxicity of [Pt(L)Cl] to both tested cell lines was low, according to MTT assays, even at loadings as high as 20 times the dose concentration for imaging for 6 h...
  64. Soultati A, Mountzios G, Avgerinou C, Papaxoinis G, Pectasides D, Dimopoulos M, et al. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer Treat Rev. 2012;38:473-83 pubmed publisher
    ..In the current review we provide a comprehensive overview of the effects of cytotoxic chemotherapeutic agents on endothelial function and the clinical implications of chemotherapy-associated endothelial toxicity in patients with cancer...
  65. Nemcova B, Bednarova I, Mikulaskova H, Beklova M. Impact of platinum on the soil invertebrate Folsomia candida. Neuro Endocrinol Lett. 2012;33 Suppl 3:173-8 pubmed
    ..Comprehensive studies on PGE behaviour and effects are still lacking. Their distribution in the food chain and data on bioaccumulation has not been described so far...
  66. Blanchard P, Hill C, Guihenneuc Jouyaux C, Baey C, Bourhis J, Pignon J. Mixed treatment comparison meta-analysis of altered fractionated radiotherapy and chemotherapy in head and neck cancer. J Clin Epidemiol. 2011;64:985-92 pubmed publisher
    ..Mixed treatment comparison (MTC) meta-analysis allows one to perform simultaneous inference regarding all treatments and select the best among them...
  67. Vu Dang L, Aggour M, Thiriaux A, Kadziolka K, Pierot L. Post-embolization perianeurysmal edema revealed by temporal lobe epilepsy in a case of unruptured internal carotid artery aneurysm treated with bare platinum coils. J Neuroradiol. 2009;36:298-300 pubmed publisher
    ..Epilepsy as a clinical presentation of perianeurysmal edema has not previously been reported. Literature about post-embolization perianeurysmal edema is reviewed...
  68. Cvetković G, Plavec G, Tomić I, Ilic V, Magic Z, Tatomirovic Z, et al. [K-ras mutation predictive significance in platinum based chemotherapeutic protocols in patients with advanced non-small cell lung cancer]. Vojnosanit Pregl. 2009;66:149-55 pubmed
    ..K-ras oncogene is mutated in about 20% of lung cancer. The purpose of this study was to investigate the predictive significance for therapeutic response of K-ras mutations in advanced non-small cell lung cancer (NSCLC) patients...
  69. Cannon L, Kereiakes D, Mann T, Popma J, Mooney M, Mishkel G, et al. A prospective evaluation of the safety and efficacy of TAXUS Element paclitaxel-eluting coronary stent implantation for the treatment of de novo coronary artery lesions in small vessels: the PERSEUS Small Vessel trial. EuroIntervention. 2011;6:920-7, 1-2 pubmed publisher
    ..TAXUS Element is a novel thin-strut, platinum chromium stent designed to enhance visibility, conformability, and drug delivery in small diameter vessels...
  70. Roy S, Aravind P, Madhurantakam C, Ghosh A, Sankaranarayanan R, Das A. Crystal structure of a fungal protease inhibitor from Antheraea mylitta. J Struct Biol. 2009;166:79-87 pubmed
    ..This study addresses the structural basis of AmFPI-1's specificity towards a fungal serine protease but not to mammalian trypsin and may help in designing specific inhibitors against fungal proteases...
  71. Wang H, Wu Z, Liu Y, Wang Y. Influences of various Pt dopants over surface platinized TiO2 on the photocatalytic oxidation of nitric oxide. Chemosphere. 2009;74:773-8 pubmed publisher
    ..The photocatalytic activity of the 0.05 at% PtOx-TiO(2) was nearly three times higher than that of the pure Degussa P25 with an inlet NO concentration of 200 ppm...
  72. Davuluri R, Jiang W, Fang P, Xu C, Komaki R, Gomez D, et al. Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy. Int J Radiat Oncol Biol Phys. 2017;99:128-135 pubmed publisher
    ..This observation provides a rationale to prospectively test chemotherapeutic and radiation treatment strategies that may have a lower impact on host immunity. ..
  73. Feldman D, Voss M, Jacobsen E, Jia X, Suarez J, Turkula S, et al. Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older. Cancer. 2013;119:2574-81 pubmed publisher
    ..Germ cell tumors (GCTs) primarily affect adolescent and young adult men. Detailed clinical and treatment characteristics in older men are lacking...
  74. Bednarova I, Haasova V, Mikulaskova H, Nemcova B, Strakova L, Beklova M. Comparison of the effect of platinum on producers in aquatic environment. Neuro Endocrinol Lett. 2012;33 Suppl 3:107-12 pubmed
    ..05; 0.01; 0.25; 0.5; 1 µM. The duckweed (Lemna minor) experiment was conducted according to OECD 221, employed PtCl4 concentrations were: 5; 10; 25; 50; 100 µM. Plants were cultivated as a microbiotest, using micro-volumes...
  75. Zhan X, Wu W, Han B, Gao G, Qiao R, Lv J, et al. Hsa-miR-196a2 functional SNP is associated with severe toxicity after platinum-based chemotherapy of advanced nonsmall cell lung cancer patients in a Chinese population. J Clin Lab Anal. 2012;26:441-6 pubmed publisher
    ..Rs11614913 is a polymorphism in hsa-miR-196a2 reported to alter mature microRNA expression and function. This single-nucleotide polymorphism (SNP) was reported to be associated with susceptibility and prognosis of lung cancer...
  76. Chen J, Zhao Q, Shi G, Wang L. XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies. J Zhejiang Univ Sci B. 2012;13:875-83 pubmed publisher
    ..To obtain the association between XRCC1 polymorphism and clinical outcome of platinum-based treatment for NSCLC, a meta-analysis was conducted...
  77. Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30:2654-63 pubmed publisher
    ..The impact of germ-line mutation on response requires further investigation to understand its impact on treatment planning and clinical trial design...
  78. Liu J, Sun R, Leung C, Lok C, Che C. Inhibition of TNF-? stimulated nuclear factor-kappa B (NF-?B) activation by cyclometalated platinum(II) complexes. Chem Commun (Camb). 2012;48:230-2 pubmed publisher
    ..Cyclometalated platinum(II) complexes [Pt(II)(C^N^N)(C?NR)](+) (HC^N^N = 6-phenyl-2,2'-bipyridyl) display significant inhibition towards TNF-? stimulated NF-?B-dependent gene transcription at concentrations down to the micromolar range...
  79. Rustin G, van der Burg M, Griffin C, Guthrie D, Lamont A, Jayson G, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376:1155-63 pubmed publisher
    ..In the MRC OV05/EORTC 55955 collaborative trial, we aimed to establish the benefits of early treatment on the basis of increased CA125 concentrations compared with delayed treatment on the basis of clinical recurrence...
  80. de Haas E, Zwart N, Meijer C, Suurmeijer A, Meijer K, Guchelaar H, et al. Association of PAI-1 gene polymorphism with survival and chemotherapy-related vascular toxicity in testicular cancer. Cancer. 2010;116:5628-36 pubmed publisher
  81. Mo J, Luo M, Cui J, Zhou S. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy. Int J Clin Exp Pathol. 2015;8:15065-71 pubmed
    ..19, 95% CI = 1.42-30.60). In conclusion, the ERCC1 rs3212986 polymorphism was found to influence the response to chemotherapy and overall survival of gastric cancer patients. ..
  82. Mügge C, Micheucci E, Boscaro F, Gabbiani C, Messori L, Weigand W. Reactions of metallodrugs with proteins: selective binding of phosphane-based platinum(II) dichlorides to horse heart cytochrome c probed by ESI MS coupled to enzymatic cleavage. Metallomics. 2011;3:987-90 pubmed publisher
    ..A remarkable selectivity in terms of adduct stoichiometry is highlighted and the specific metal binding sites are localised on the protein surface...
  83. Chu P, Lu C, Sheng X, Zhou C, Li D, Du X, et al. [Gemcitabine based combination chemotherapy, a new salvage regimen for recurrent platinum resistant epithelial ovarian cancer]. Zhonghua Fu Chan Ke Za Zhi. 2010;45:808-12 pubmed
    ..To evaluate the efficacy and toxicities of gemcitabine combined with ifosfamide and anthracycline chemotherapy for recurrent platinum resistant ovarian epithelial cancer...
  84. Garner K, Parkes L, Piper J, Williams J. Luminescent platinum complexes with terdentate ligands forming 6-membered chelate rings: advantageous and deleterious effects in N--N--N and N--C--N-coordinated complexes. Inorg Chem. 2010;49:476-87 pubmed publisher
    ..The cyclometalated complex PtL(4)Cl emits at lower energy than [PtL(1)Cl](+) but, in this case, the luminescence quantum yield is inferior to related complexes with 5-membered chelate rings...